Basel, October 28, 2025 - Novartis today announced that it has successfully completed its acquisitio

Basel, October 28 2025 - Novartis today announced that its previously announced tender offer (the “o

Basel, October 22, 2025 - Novartis today announced the expiration of the waiting period under the Ha

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti,

Basel, September 29, 2025 - Novartis today announced that Torino Merger Sub Inc., a Delaware corpora

NEW YORK , Sept. 15, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & A

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti,

Novartis is set to acquire Tourmaline Bio for $1.4B, adding late-stage anti-IL-6 candidate pacibekit

Tourmaline Bio (TRML) shares have had a strong run this year. News that Swiss pharma giant Novartis

Nebius surges 49% pre-market after securing a $17.4B AI infrastructure deal with Microsoft, potentia

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t

Novartis AG (ADR) (NYSE:NVS) has agreed to buy Tourmaline Bio in a $1.4 billion cash deal, strengthe

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Tourmaline (NASDAQ: TRML) for possible b

Switzerland's Novartis will acquire Tourmaline Bio with an offer price of $48 per share, in a deal v

– Novartis to acquire Tourmaline Bio for $48.00 per share in cash for a total equity value of approx

Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mA

– Poster presentation highlights the consistency of reductions in high-sensitivity C-reactive protei

The consensus price target hints at a 151% upside potential for Tourmaline Bio, Inc. (TRML). While e

– Reported positive topline results from the ongoing Phase 2 TRANQUILITY trial of pacibekitug in May